Hidden Cardiac Lesions and Psychotropic Drugs as a Possible Cause of Sudden Death in Psychiatric Patients: A Report of 14 Cases and Review of the Literature

Canadian Journal of Psychiatry

Volumn 49, Issue 2, 2004, Pages 100-105

  Frassati, Dominique ^a   Tabib, Alain ^b   Lachaux, Bernard ^c   Giloux, Natalie ^a   Daléry, Jean ^a   Vittori, François ^d   Charvet, Dorothée ^d   Barel, Cécile ^e   Bui Xuan, Bernard ^e   Mégard, Rachel ^a   Jenoudet, Louis Pierre ^a   Descotes, Jacques ^e   Vial, Thierry ^e   Timour, Quadiri ^e  

^a CENTRE HOSPITALIER LE VINATIER   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c Centre Hospitalier Paul Guiraud   (France)

^d Hopital Saint Jean de Dieu   (France)

^e Centre de Pharmacovigilance   (France)

Author keywords

Cardiotoxicity; Hidden cardiac lesions; Pathological examination; Psychotropic drugs; Reentrant arrhythmia; Sudden death; Torsades de pointes

Indexed keywords

AMIODARONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FUROSEMIDE; LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; ASPIRATION PNEUMONIA; AUTOPSY; BRAIN; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG OVERDOSE; FEMALE; GASTROINTESTINAL TRACT; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FIBRILLATION; HIS BUNDLE; HUMAN; LUNG; MALE; MEDICAL LITERATURE; MENTAL DISEASE; MENTAL PATIENT; MITRAL VALVE PROLAPSE; PSYCHOPHARMACOTHERAPY; QRS COMPLEX; QT PROLONGATION; REVIEW; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES; TOXICOLOGY;

EID: 12144288525     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900204     Document Type: Review

References (48)

1. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-45.
2. Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH, and others. Sudden death in psychiatric patients. Br J Psychiatry 1998;172:331-6.
3. Hansen V, Arnessen E, Jacobsen BK. Total mortality in people admitted to a psychiatric hospital. Br J Psychiatry 1997;170:186-90.
4. Di-Giacomo J. Cardiovascular effects of psychotropic drugs. Cardiovasc Rev Rep 1989;10:31-47.
5. Reilly JG, Ayis SA, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-52.
6. Committee of Medicines/Medicines Control Agency. Drug induced neutropenia and agranulocytosis. Current problems 1993; 19: 10-11
7. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345:224.
8. Blackwell B. Antidepressant drugs. In: Dukes MNG, editor. Side-effects of drugs annual 10. Amsterdam: Elsevier; 1986. p 15-26
9. Spier SA, Frontera MA. Unexpected death in depressed medical inpatients treated with fluoxetine. J Clin Psychiatry 1991;52:377-82.
10. Montalescot G, Levy H, Hatt PY. Serious sinus node dysfunction caused by therapeutic doses of lithium. Int J Cardiol 1984;5:94-6.
11. Palileo EV, Coelho A, Westveer D, Dhingra R, Rosen KM. Persistent sinus node dysfunction secondary to lithium therapy. Am Heart J 1983;106:1443-4.
12. Martin CA, Pisascik MT. First A-V block in patients on lithium carbonate. Can J Psychiatry 1985;30:114-6.
13. Demers RG, Heninger GR. Electrographic T-wave changes during lithium carbonate treatment. JAMA 1971;218:381-6.
14. Snaith RP. Antipsychotic polypharmacy and early death. Br J Psychiatry 1999;174:368-9.
15. Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996;93:311-3.
16. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drug. J Clin Psychopharmacol 1998;18:477-81.
17. Mehtonen OP, Aranko J, Malkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drug: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58-64.
18. Timell AM. Thioridazine: re-evaluating the risk/benefit equation. Ann Clin Psychiatry 2000;12:147-51.
19. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
20. Gupta N, Malhotra P. Olanzapine: a proarrhythmic drug? Can J Psychiatry 2002;47:683-4.
21. Gex-Fabry M, Balant-Gorgia AE, Balant RP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53.
22. Ketai R. Interaction between fluoxetine and neuroleptics. Am J Psychiatry 1993;150:836-7.
23. Kosky N. A possible association between normal and high dose olanzapine and prolongation of the PR interval. J Psychopharmacol 2002;2:181-2.
24. Harris MG, Benfield P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in older patients with depressive illness. Drugs Aging 1995;64-84.
25. Roden DM. Torsades de pointes. Clin Cardiol 1993;16:683-6.
26. Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S, and others. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol 1992;69:628-33.
27. Jerling M, Merle Y, Mentre F, Mallet A. Population pharmacokinetics of nortriptyline during monotherapy and concomitant treatment with drugs that inhibit CYP-2D6: an evaluation with nonparametric maximum likelihood method. Br J Clin Pharmacol 1994;38:453-62
28. Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusion in patients on diuretic treatment. Am Heart J 1979;97:12-8.
29. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and sudden cardiac death. Arch Gen Psychiatry 2001;58:1168-71,
30. Huikuri HV, Castellanos A, Myerburg JJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
31. Davis JC, Bigger JT. The effects of thioridazine on electrical and ischemic ventricular fibrillation in the dog heart in situ. J Pharmacol Exp Ther 1981;216:39-44.
32. Magorien RD, Jewell GM, Schaal SF. Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation. Am J Med 1979;67:353-7.
33. Glassman AH, Bigger JT. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch Gen Psych 1981;38:815-20.
34. Disertori M, Dallafior D, Marini M. Arrhythmia risk stratification based on etiological and anatomo-structural factors. Ital Heart J 2001;2:1265-9.
35. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, and others. Lett bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002;143:398-405.
36. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, and others. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
37. Sarter BH, Finle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996;28:122-9.
38. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-6.
39. Brembilla-Perrot B, Beurrier D, Jacquemin L, Malak S, Danchin N. Quinidine and high amplification ECG. Ann Cardiol Angeiol 1997;46:15-20.
40. Yang CP, Guillan RA. Sudden death syndrome: report of 16 patients on high doses of phenothiazine. J Kans Med Soc 1979;80:547-63.
41. Chen Q, Kirsch GE, Zhng D, Brugada R, Brugada J, Brugada P, and others. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293-6.
42. Hull BE, Lockwood TD. Toxic cardiomyopathy: the effect of antipsychotic antidepressant drug and calcium on myocardial protein degradation and structural integrity. Toxicol Appl Pharmacol 1986;86:308-24.
43. Hunt N, Stern TA. The association between intravenous haloperidol and torsades de pointes. Three cases and literature review. Psychosomatics 1995;36:541-9.
44. Ravin S, Levenson J. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997;31:867-70.
45. Waslick B. Cardiac effects of desipramine. J Am Acad Child Adolesc Psychiatry 1995;34:125-6.
46. Hermann HC, Kaplan LM, Bierer BE. QT prolongation and torsades de pointes produced by tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983;51:904-6.
47. Cranefield PF, Aronson RS. Torsades de pointes and early after depolarizations. Cardiovasc Drugs Ther 1991;5:531-7.
48. Carmeliet EK. Channels and control of ventricular repolarization in the heart. Fundam Clin Pharmacol 1993;7:19-28.